Idiopathic or hypogonadal osteoporosis in men: Current and future treatment options

Treatments in Endocrinology

Volumn 3, Issue 6, 2004, Pages 381-391

  Ebeling, Peter R ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; HORMONE RECEPTOR AFFECTING AGENT; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D;

ACCIDENT PREVENTION; AGING; BONE DENSITY; BONE MASS; BONE MINERAL; CALCIUM INTAKE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET; DRUG INDICATION; EPIDEMIOLOGICAL DATA; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; EXERCISE; FALLING; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEREDITY; HORMONE BLOOD LEVEL; HUMAN; HYPOGONADAL OSTEOPOROSIS; HYPOGONADISM; IDIOPATHIC OSTEOPOROSIS; LABORATORY TEST; LIVER DISEASE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE DISEASE; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ENDOCRINOLOGY; HUMANS; HYPOGONADISM; MALE; OSTEOPOROSIS;

EID: 9144233577     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403060-00006     Document Type: Review

References (85)

1. Sambrook PN, Seeman E, Phillips S, et al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust 2002; 176: S1-16
2. Cooley H, Jones G. A population based study of fracture incidence in southern Tasmania: lifetime fracture risk and evidence for geographic variations within the same country. Osteoporosis Int 2001; 12: 124-30
3. Bilezikian JP. Gender specificity and osteoporosis. J Gend Specif Med 2000; 3 (7): 6-12
4. Gullberg B, Johnell O, Kanis JA. World-wide projections for hip fracture. Osteoporos Int 1997; 7 (5): 407-13
5. Sanders KM, Nicholson GC, Ugoni AM, et al. Health burden of hip and other fractures in Australia beyond 2000: projections based on the Geelong Osteoporosis Study. Med J Aust 1999; 170 (10): 467-70
6. Jones G, Nguyen T, Sambrook P, et al. Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 1994 309: 691-5
7. Johnell O, Kanis J, Gullberg G. Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 2001; 69 (4): 182-4
8. Poor G, Atkinson EJ, Lewallen DG, et al. Age-related hip fractures in men: clinical spectrum and short-term outcomes. Osteoporos Int 1995; 5: 419-26
9. Diamond T, Smerdely P, Kormas N, et al. Hip fracture in elderly men: the importance of subclinical vitamin D deficiency and hypogonadism. Med J Aust 1998; 169: 138-41
10. Colon-Emeric CS, Sloane R, Hawkes WG, et al. The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture. Am J Med 2000; 109: 324-6
11. Jones G, White C, Nguyen T, et al. Prevalent vertebral deformities: relationship to bone mineral density and spinal osteophytosis in elderly men and women. Osteoporos Int 1996; 6: 233-9
12. O'Neill T, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11: 1010-8
13. Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester. Minnesota, 1985-1989. J Bone Miner Res 1992; 7: 221-7
14. Lombardi A, Ross PD. The assessment of bone mass in men. Calcif Tissue Int 2001; 69: 222-4
15. de Laet CE, van der Klift M, Hofman A, et al. Osteoporosis in men and women: a story about bone mineral density thresholds and hip fracture risk. J Bone Miner Res 2002; 17: 2231-6
16. Center J, Nguyen TV, Sambrook PN, et al. Hormonal and biochemical parameters in the determination of osteoporosis in elderly men. J Clin Endocrinol Metab 1999; 84: 3626-35
17. Hannan M, Felson DT, Dawson-Hughes B, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 2000; 15: 710-20
18. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16: 87-116
19. Ebeling PR. Osteoporosis in men: new insights into aetiology, pathogenesis, prevention and management. Drugs Aging 1998; 13: 421-34
20. Khosla S, Melton III LJ, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87: 1443-50
21. Vanderschueren D, Boonen S, Ederveen AG, et al. Skeletal effects of estrogen deficiency as induced by an aromatase inhibitor in an aged male rat model. Bone 2000; 27: 611-7
22. Reutrakul S, Ongphiphadhanakul B, Piaseu N, et al. The effects of oestrogen exposure on bone mass in male to female transsexuals. Clin Endocrinol 1998; 49: 811-4
23. Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056-61
24. Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689-98
25. Bilezikian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339: 599-603
26. Oz OK, Zerwekh JE, Fisher C, et al. Bone has a sexually dimorphic response to aromatase deficiency. J Bone Miner Res 2000; 15: 507-14
27. Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable oestrogen. J Clin Endocrinol Metab 1998; 83: 2266-74
28. Slemenda CW, Longcope C, Zhou L, et al. Sex steroids and bone mass in older men: positive association with serum oestrogens and negative associations with androgens. J Clin Invest 1997; 100: 1755-9
29. Greendale GA, Edelstein S, Barrett-Connor E. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo study. J Bone Miner Res 1997; 12: 1833-43
30. Tenover JS, Matsumoto AM, Plymate SR, et al. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate. J Clin Endocrinol Metab 1987; 65: 1118-26
31. Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, et al. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol (Oxf) 1998; 49: 803-9
32. van den Beld AW, de Jong FH, Grobbee DE, et al. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density and body composition in elderly men. J Clin Endocrinol Metab 2000; 85: 3276-82
33. Amin S, Zhang Y, Swain CT, et al. Association of hypogonadism and estradiol levels with bone mineral density in older men from the Framingham study. Ann Intern Med 2000; 133: 951-63
34. Szulc P, Munoz F, Claustrat B, et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the M1NOS study. J Clin Endocrinol Metab 2001; 86: 192-9
35. Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of sex steroids to longitudinal changes in bone mineral density and bone resorption in young versus elderly men: effects of estrogen on peak bone mass and on age-related bone loss. J Clin Endocrinol Metab 2001; 86: 3555-61
36. Barrett-Connor E, Mueller JE, von Muhlen DG, et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85: 219-23
37. Turner RT, Colvard DS, Spelsberg TC. Estrogen inhibition of periosteal bone formation in rat long bones: down-regulation of gene expression for bone matrix proteins. Endocrinology 1990; 127: 1346-51
38. Windahl SH, Vidal O, Anderrson G, et al. Increased cortical bone mineral content but unchanged bone mineral density in female ERbeta(-/-) mice. J Clin Invest 1999; 104: 895-901
39. Riggs BL, Khosla S, Melton III LJ. Sex steroids and the construction and conservation of the skeleton. Endocr Rev 2002; 23: 279-302
40. Falahati-Nini A, Riggs BL, Atkinson EJ, et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106: 1553-60
41. Khosla SK, Atkinson EJ, Dunstan CR, et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002; 87: 1550-4
42. Lorentzom M, Lorentzom R, Backstrom T, et al. Estrogen receptor gene polymorphism, but not estradiol levels, is related to bone density in healthy adolescent boys: a cross-sectional and longitudinal study. J Clin Endocrinol Metab 1999; 84: 4597-601
43. Allcroft LC, Varanasi SS, Dimopoulos D, et al. Mutational and polymorphic analysis of the estradiol receptor-alpha gene in men with symptomatic vertebral fractures. Calcif Tissue Int 2002; 71: 400-5
44. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22: 477-501
45. Fuchs RK, Bauer JJ, Snow CM. Jumping improves hip and lumbar spine bone mass in prepubescent children: a randomised controlled trial. J Bone Miner Res 2001; 16: 148-56
46. Flicker L, Mead K, MacInnis RJ, et al. Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc 2003; 51 (11): 1533-8
47. Bischoff HA, Stahelin HB, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomised controlled trial. J Bone Miner Res 2003; 18: 343-51
48. Blumsohn A, Herrington K, Hannon RA, et al. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab 1994; 79 (3): 730-5
49. O'Neill S, Sambrook PN, Diamond T, et al. Guidelines for the treatment of postmenopausal osteoporosis for general practitioners. Aust Fam Physician 2002; 31: 921-8
50. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1993; 327: 1637-42
51. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003; 326: 469-74
52. Skull SA, Ngeow JY, Biggs BA, et al. Vitamin D deficiency is common and unrecognised among recently arrived adult immigrants from The Horn of Africa. Intern Med J 2003; 33: 47-51
53. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670-6
54. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 2000; 72: 745-50
55. Trovas GP, Lyritis GP, Galanos A, et al. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 2002; 18: 521-7
56. Ebeling PR, Wark JD, Yeung S, et al. Effects of calcium or calcitriol on bone mineral density, bone turnover and fractures in men with primary osteoporosis. J Clin Endocrinol Metab 2001; 86: 4098-103
57. Vanderschueren D, Boonen S, Bouillon R. Actions of androgens versus estrogens in male skeletal homeostasis. Bone 1998; 23 (5): 391-4
58. Finklestein JS, Neer RM, Biller BM, et al. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992; 326: 600-4
59. Finklestein JS, Klibamski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with a history of delayed puberty. J Clin Endocrinol Metab 1996; 81: 1152-5
60. Abbasi AA, Rudman D, Wilson CR, et al. Observations on nursing home patients with a history of hip fracture. Am J Med Sci 1995; 310: 229-34
61. Oefelein M, Riccchuiti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 2001; 166: 1724-8
62. Finklestein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotrophic hypogonadism. J Clin Endocrinol Metab 1989; 69: 776-83
63. van der Werff ten Bosch JJ, Bot A. Some skeletal dimensions of males with isolated gonadotrophin deficiency. Neth J Med 1992; 41: 259-63
64. Katznelson L, Finklestein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358-65
65. Leder BZ, Smith MR, Fallon MA, et al. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab 2001; 86: 511-6
66. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966-72
67. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-53
68. Anderson F, Francis RM, Faulkner K. Androgen supplementation in eugonadal men with osteoporosis: effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 1996; 18: 171-7
69. Anderson F, Francis RM, Peaston RT, et al. Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J Bone Miner Res 1997; 12: 472-8
70. Reid I, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173-7
71. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-10
72. Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998; 91: 71-92
73. Reid DM, Adami S, Devogelaer JP, et al. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69: 242-7
74. Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86: 957-64
75. Ringe JD, Dorst A, Kipshoven C, et al. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate. Osteoporosis Int 1998; 8: 47-52
76. Meunier PJ, Sebert JL, Reginster JY, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOS study. Osteoporos Int 1998; 8: 4-12
77. Reeve J, Meunier PJ, Parsons JA, et al. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. BMJ 1980; 280: 1340-4
78. Slovik DM, Rosenthal DI, Doppelt SH, et al. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxy vitamin D. J Bone Miner Res 1986; 1: 377-81
79. Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-76
80. Bilezikian JP, Kurland ES. Therapy of male osteoporosis with parathyroid hormone. Calcif Tissue Int 2001; 69: 248-51
81. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17
82. Orwoll E, Scheele WD, Clancy AD, et al. Recombinant human parathyroid hormone (1-34) therapy reduces the incidence of moderate/severe vertebral fractures in men with low bone density [abstract]. J Bone Miner Res 2001; 16 Suppl.: S162
83. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41
84. Doran PM, Riggs BL, Atkinson EJ, et al. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001; 16: 2118-25
85. Negro-Vilar A. Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. J Clin Endocrinol Metab 1999; 84: 3459-62